人胰岛素药物市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按产品类型(传统人胰岛素、基础或长效胰岛素、丸剂或速效胰岛素、胰岛素组合和生物仿制胰岛素)和地理位置进行细分。

市场快照

Human Insulin Drugs Market Size
Study Period: 2016-2027
Base Year: 2021
Fastest Growing Market: North America
Largest Market: North America
CAGR: 4.19 %
Human Insulin Drugs Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

在 2020-2025 年的预测期内,人用胰岛素药物市场的复合年增长率预计为 4.19%,预计到 2025 年将达到 299 亿美元。糖尿病通常被认为是一种与生活方式有关的疾病。随着时间的推移,随着世界各地人口的增加,这种疾病的发病率急剧增加。全世界约有 1 亿人需要胰岛素,包括所有 1 型糖尿病患者和 10-25% 的 2 型糖尿病患者。尽管胰岛素用于治疗糖尿病已有 90 多年的历史,但在全球范围内,今天需要胰岛素的人中有一半以上仍然无法负担和获得它。1 型糖尿病患者需要胰岛素治疗,该治疗的重点是控制血糖水平以及胰岛素、饮食和生活方式,以预防并发症。

报告范围

研究涵盖以下几个方面:

By Product Type
Basal or Long-acting Insulins (Value and Volume, 2012-2025)
Lantus (Insulin glargine)
Levemir (Insulin detemir)
Toujeo (Insulin glargine)
Tresiba (Insulin degludec)
Basaglar (Insulin glargine)
Bolus or Fast-acting Insulins (Value and Volume, 2012-2025)
NovoRapid/Novolog (Insulin aspart)
Humalog (Insulin lispro)
Apidra (Insulin glulisine)
FIASP (Insulin aspart)
Admelog (Insulin lispro)
Traditional Human Insulins (Value and Volume, 2012-2025)
Novolin/Actrapid/Insulatard
Humulin
Insuman
Combination Insulins (Value and Volume, 2012-2025)
NovoMix (Biphasic Insulin aspart)
Ryzodeg (Insulin degludec/Insulin aspart)
Xultophy (Insulin degludec/Liraglutide)
Soliqua/Suliqua (Insulin glargine/Lixisenatide)
Biosimilar Insulins (Value and Volume, 2012-2025)
Insulin Glargine Biosimilars
Human Insulin Biosimilars
Geography
North America
United States (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Canada (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of North America (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Europe
France (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Germany (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Italy (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Spain (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
United Kingdom (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Russia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Europe (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Latin America
Mexico (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Brazil (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Latin America (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Asia-Pacific
Japan (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
South Korea (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
China (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
India (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Australia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Vietnam (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Malaysia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Indonesia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Philippines (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Thailand (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Asia-Pacific (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Middle-East and Africa
Saudi Arabia (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Iran (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Egypt (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Oman (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
South Africa (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins
Rest of Middle-East and Africa (Value and Volume, 2012-2025)
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins

Report scope can be customized per your requirements. Click here.

主要市场趋势

不断增长的糖尿病患病率推动市场

全世界大约有 1 亿人需要胰岛素,包括所有 1 型糖尿病患者和 10-25% 的 2 型糖尿病患者。尽管 90 多年来,胰岛素已在世界范围内用于治疗糖尿病,但如今仍有一半以上需要胰岛素的人口负担不起或无法获得它。1 型糖尿病患者需要胰岛素治疗,治疗的重点是通过胰岛素、饮食和生活方式控制血糖水平,以预防并发症。胰岛素领域的研发正在逐年上升,因为研究人员正试图为患者提供最好的分子,抑制最大的副作用,并提高他们的效率。因此,全世界肥胖和糖尿病患病率的增加可能会增加对胰岛素的大量需求,

Human Insulin Drugs Market Share

北美主导市场

由于久坐不动的生活方式,该地区的糖尿病患病率很高,北美在全球人类胰岛素市场上占主导地位,尤其是在美国。成本因素是美国的主要关注点,制造商近 50% 的胰岛素收入来自该国本身。美国是全球长效胰岛素Lantus销量最高的国家。大多数糖尿病药物制造公司认为该国是提高全球整体销售的关键市场。来得时是全球使用量最大的基础胰岛素,在美国市场占有主导地位。由于患者的经济承受能力,传统的北美人胰岛素药物市场预计将在预测期内增长。Humulin 拥有最高的市场份额,其次是 Novolin。美国传统的北美人胰岛素药物市场没有仿制药竞争对手。

Human Insulin Drugs Market Analysis

竞争格局

全球人胰岛素市场高度整合,三大制造商在全球市场占有一席之地,其余制造商仅限于其他本地或特定地区的制造商。近期参与者之间发生的合并和收购帮助这些公司加强了他们的市场占有率。礼来(Eli Lilly)和勃林格殷格翰(Boehringer Ingelheim)共同开发和商业化 Basaglar(甘精胰岛素)。

正在开发的胰岛素:

诺和诺德正在开发第一个每周一次的长效胰岛素 (LAI287),目前处于 2 期。该胰岛素适用于 1 型和 2 型糖尿病患者。Eli Lilly正在开发一种长效胰岛素-Fc (LY3209590)。“基础胰岛素-Fc”是一种大分子,由与 Fc 域融合的工程化胰岛素组成,旨在提供长效基础特征。LY3209590 正在研究用于治疗糖尿病。

口服胰岛素的药物将推动市场:

Biocon正在开发Insulin Tregopil,一种口服餐时胰岛素片剂,用于治疗 1 型和 2 型糖尿病。速效口服胰岛素可以改善餐后血糖控制,减少副作用并提高依从性,从而有望改变 T1D 管理。Oramed Pharmaceuticals Inc. 是一家临床阶段的制药公司,专注于口服给药系统的开发,正在努力将第一个口服胰岛素产品推向市场,从而为治疗提供更方便、更有效、更安全的方法。提供胰岛素治疗。

LIST OF TABLES AND FIGURES

 

LIST OF TABLES

1 Global Human Insulin Drugs Market: Revenue in USD million, by Product Type, 2012 - 2024
2 Global Human Insulin Drugs Market: Revenue in USD million, by Basal or Long-acting Insulins, 2012-2024
3 Global Human Insulin Drugs Market: Revenue in USD million, by Bolus or Fast-acting Insulins, 2012-2024
4 Global Human Insulin Drugs Market: Revenue in USD million, by Traditional Human Insulins, 2012-2024
5 Global Human Insulin Drugs Market: Revenue in USD million, by Combination Insulins, 2012-2024
6 Global Human Insulin Drugs Market: Revenue in USD million, by Biosimilar Insulins, 2012-2024
7 Global Human Insulin Drugs Market: Revenue in USD million, by Geography, 2012-2024
8 Global Human Insulin Drugs Market: Revenue in USD million, by North America, 2012-2024
9 Global Human Insulin Drugs Market: Revenue in USD million, by United States, by Segmentation, 2012-2024
10 Global Human Insulin Drugs Market: Revenue in USD million, by Canada, by Segmentation, 2012-2024
11 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of North America, by Segmentation, 2012-2024
12 Global Human Insulin Drugs Market: Revenue in USD million, by Europe, 2012-2024
13 Global Human Insulin Drugs Market: Revenue in USD million, by United Kingdom, by Segmentation, 2012-2024
14 Global Human Insulin Drugs Market: Revenue in USD million, by Germany, by Segmentation, 2012-2024
15 Global Human Insulin Drugs Market: Revenue in USD million, by France, by Segmentation, 2012-2024
16 Global Human Insulin Drugs Market: Revenue in USD million, by Italy, by Segmentation, 2012-2024
17 Global Human Insulin Drugs Market: Revenue in USD million, by Spain, by Segmentation, 2012-2024
18 Global Human Insulin Drugs Market: Revenue in USD million, by Russia, by Segmentation, 2012-2024
19 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of Europe, by Segmentation, 2012-2024
20 Global Human Insulin Drugs Market: Revenue in USD million, by Latin America, 2012-2024
21 Global Human Insulin Drugs Market: Revenue in USD million, by Mexico, by Segmentation, 2012-2024
22 Global Human Insulin Drugs Market: Revenue in USD million, by Brazil, by Segmentation, 2012-2024
23 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of Latin America, by Segmentation, 2012-2024
24 Global Human Insulin Drugs Market: Revenue in USD million, by Asia-Pacific, 2012-2024
25 Global Human Insulin Drugs Market: Revenue in USD million, by Japan, by Segmentation, 2012-2024
26 Global Human Insulin Drugs Market: Revenue in USD million, by South Korea, by Segmentation, 2012-2024
27 Global Human Insulin Drugs Market: Revenue in USD million, by China, by Segmentation, 2012-2024
28 Global Human Insulin Drugs Market: Revenue in USD million, by India, by Segmentation, 2012-2024
29 Global Human Insulin Drugs Market: Revenue in USD million, by Australia, by Segmentation, 2012-2024
30 Global Human Insulin Drugs Market: Revenue in USD million, by Vietnam, by Segmentation, 2012-2024
31 Global Human Insulin Drugs Market: Revenue in USD million, by Malaysia, by Segmentation, 2012-2024
32 Global Human Insulin Drugs Market: Revenue in USD million, by Indonesia, by Segmentation, 2012-2024
33 Global Human Insulin Drugs Market: Revenue in USD million, by Philippines, by Segmentation, 2012-2024
34 Global Human Insulin Drugs Market: Revenue in USD million, by Thailand, by Segmentation, 2012-2024
35 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of Asia-Pacific, by Segmentation, 2012-2024
36 Global Human Insulin Drugs Market: Revenue in USD million, by Middle East and Africa, 2012-2024
37 Global Human Insulin Drugs Market: Revenue in USD million, by Saudi Arabia, by Segmentation, 2012-2024
38 Global Human Insulin Drugs Market: Revenue in USD million, by Iran, by Segmentation, 2012-2024
39 Global Human Insulin Drugs Market: Revenue in USD million, by Egypt, by Segmentation, 2012-2024
40 Global Human Insulin Drugs Market: Revenue in USD million, by Oman, by Segmentation, 2012-2024
41 Global Human Insulin Drugs Market: Revenue in USD million, by South Africa, by Segmentation, 2012-2024
42 Global Human Insulin Drugs Market: Revenue in USD million, by Rest of Middle and Africa, by Segmentation, 2012-2024
43 Global Human Insulin Drugs Market: Revenue in USD million, by Market Indicators, 2012-2024

 

LIST OF FIGURES

1 Global Human Insulin Drugs Market, Revenue in USD million, 2012-2024
2 Global Countries Diabetes Population 2012-2024
3 Global Countries with High Obese Population, 2018
4 Global Human Insulin Drugs Market: Revenue in USD million, by Basal or Long-acting Insulins, 2012-2024
5 Global Human Insulin Drugs Market: Revenue in USD million, by Bolus or Fast-acting Insulins, 2012-2024
6 Global Human Insulin Drugs Market: Revenue in USD million, by Traditional Human Insulins, 2012-2024
7 Global Human Insulin Drugs Market: Revenue in USD million, by Combination Insulins, 2012-2024
8 Global Human Insulin Drugs Market: Revenue in USD million, by Biosimilar Insulins, 2012-2024
9 Global Human Insulin Drugs Market: Revenue in USD million, United States, 2012-2024
10 Global Human Insulin Drugs Market: Revenue in USD million, Canada, 2012-2024
11 Global Human Insulin Drugs Market: Revenue in USD million, Rest of North America, 2012-2024
12 Global Human Insulin Drugs Market: Revenue in USD million, United Kingdom, 2012-2024
13 Global Human Insulin Drugs Market: Revenue in USD million, Germany, 2012-2024
14 Global Human Insulin Drugs Market: Revenue in USD million, France, 2012-2024
15 Global Human Insulin Drugs Market: Revenue in USD million, Italy, 2012-2024
16 Global Human Insulin Drugs Market: Revenue in USD million, Spain, 2012-2024
17 Global Human Insulin Drugs Market: Revenue in USD million, Russia, 2012-2024
18 Global Human Insulin Drugs Market: Revenue in USD million, Rest of Europe, 2012-2024
19 Global Human Insulin Drugs Market: Revenue in USD million, Japan, 2012-2024
20 Global Human Insulin Drugs Market: Revenue in USD million, South Korea, 2012-2024
21 Global Human Insulin Drugs Market: Revenue in USD million, China, 2012-2024
22 Global Human Insulin Drugs Market: Revenue in USD million, India, 2012-2024
23 Global Human Insulin Drugs Market: Revenue in USD million, Australia, 2012-2024
24 Global Human Insulin Drugs Market: Revenue in USD million, Vietnam, 2012-2024
25 Global Human Insulin Drugs Market: Revenue in USD million, Malaysia, 2012-2024
26 Global Human Insulin Drugs Market: Revenue in USD million, Indonesia,  2012-2024
27 Global Human Insulin Drugs Market: Revenue in USD million, Philippines, 2012-2024
28 Global Human Insulin Drugs Market: Revenue in USD million, Thailand, 2012-2024
29 Global Human Insulin Drugs Market: Revenue in USD million, Rest of Asia-Pacific, 2012-2024
30 Global Human Insulin Drugs Market: Revenue in USD million, Saudi Arabia, 2012-2024
31 Global Human Insulin Drugs Market: Revenue in USD million, Iran, 2012-2024
32 Global Human Insulin Drugs Market: Revenue in USD million, Egypt, 2012-2024
33 Global Human Insulin Drugs Market: Revenue in USD million, Oman, 2012-2024
34 Global Human Insulin Drugs Market: Revenue in USD million, South Africa, 2012-2024
35 Global Human Insulin Drugs Market: Revenue in USD million, Rest of Middle and Africa, 2012-2024
36 Novo Nordisk AS Diabetes Care Revenue in USD million, 2016-2018
37 Novo Nordisk AS Diabetes Care Revenue Breakdown -  By Division (2018)
38 Novo Nordisk AS Diabetes Care Revenue Breakdown -  By Geographic Segment (2018)
39 Sanofi Aventis Revenue in USD million, 2016-2018
40 Sanofi Aventis Revenue Breakdown -  By Division (2018)
41 Sanofi Aventis Revenue Breakdown -  By Geographic Segment (2018)
42 Eli Lilly Revenue in USD million, 2016-2018
43 Eli Lilly Revenue Breakdown -  By Division (2018)
44 Eli Lilly Revenue Breakdown -  By Geographic Segment (2018)
45 Biocon Revenue in USD million, 2016-2018
46 Biocon Revenue Breakdown -  By Division (2018)
47 Biocon Revenue Breakdown -  By Geographic Segment (2018)
48 Pfizer Revenue in USD million, 2016-2018
49 Pfizer Revenue Breakdown -  By Division (2018)
50 Pfizer Revenue Breakdown -  By Geographic Segment (2018)
51 Julphar Revenue in USD million, 2016-2018
52 Julphar Revenue Breakdown -  By Division (2018)
53 Julphar Revenue Breakdown -  By Geographic Segment (2018)
54 Exir Revenue in USD million, 2016-2018
55 Exir Revenue Breakdown -  By Division (2018)
56 Exir Revenue Breakdown -  By Geographic Segment (2018)
57 Sedico Revenue in USD million, 2016-2018
58 Sedico Revenue Breakdown -  By Division (2018)
59 Sedico Revenue Breakdown -  By Geographic Segment (2018)
60 Wockhardt Revenue in USD million, 2016-2018
61 Wockhardt Revenue Breakdown -  By Division (2018)
62 Wockhardt Revenue Breakdown -  By Geographic Segment (2018)
63 Company Share Analysis (2018)

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Drivers

    3. 4.3 Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2025)

        1. 5.1.1.1 Lantus (Insulin glargine)

        2. 5.1.1.2 Levemir (Insulin detemir)

        3. 5.1.1.3 Toujeo (Insulin glargine)

        4. 5.1.1.4 Tresiba (Insulin degludec)

        5. 5.1.1.5 Basaglar (Insulin glargine)

      2. 5.1.2 Bolus or Fast-acting Insulins (Value and Volume, 2012-2025)

        1. 5.1.2.1 NovoRapid/Novolog (Insulin aspart)

        2. 5.1.2.2 Humalog (Insulin lispro)

        3. 5.1.2.3 Apidra (Insulin glulisine)

        4. 5.1.2.4 FIASP (Insulin aspart)

        5. 5.1.2.5 Admelog (Insulin lispro)

      3. 5.1.3 Traditional Human Insulins (Value and Volume, 2012-2025)

        1. 5.1.3.1 Novolin/Actrapid/Insulatard

        2. 5.1.3.2 Humulin

        3. 5.1.3.3 Insuman

      4. 5.1.4 Combination Insulins (Value and Volume, 2012-2025)

        1. 5.1.4.1 NovoMix (Biphasic Insulin aspart)

        2. 5.1.4.2 Ryzodeg (Insulin degludec/Insulin aspart)

        3. 5.1.4.3 Xultophy (Insulin degludec/Liraglutide)

        4. 5.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)

      5. 5.1.5 Biosimilar Insulins (Value and Volume, 2012-2025)

        1. 5.1.5.1 Insulin Glargine Biosimilars

        2. 5.1.5.2 Human Insulin Biosimilars

    2. 5.2 Geography

      1. 5.2.1 North America

        1. 5.2.1.1 United States (Value and Volume, 2012-2025)

          1. 5.2.1.1.1 Basal or Long-acting Insulins

          2. 5.2.1.1.2 Bolus or Fast-acting Insulins

          3. 5.2.1.1.3 Traditional Human Insulins

          4. 5.2.1.1.4 Combination Insulins

          5. 5.2.1.1.5 Biosimilar Insulins

        2. 5.2.1.2 Canada (Value and Volume, 2012-2025)

          1. 5.2.1.2.1 Basal or Long-acting Insulins

          2. 5.2.1.2.2 Bolus or Fast-acting Insulins

          3. 5.2.1.2.3 Traditional Human Insulins

          4. 5.2.1.2.4 Combination Insulins

          5. 5.2.1.2.5 Biosimilar Insulins

        3. 5.2.1.3 Rest of North America (Value and Volume, 2012-2025)

          1. 5.2.1.3.1 Basal or Long-acting Insulins

          2. 5.2.1.3.2 Bolus or Fast-acting Insulins

          3. 5.2.1.3.3 Traditional Human Insulins

          4. 5.2.1.3.4 Combination Insulins

          5. 5.2.1.3.5 Biosimilar Insulins

      2. 5.2.2 Europe

        1. 5.2.2.1 France (Value and Volume, 2012-2025)

          1. 5.2.2.1.1 Basal or Long-acting Insulins

          2. 5.2.2.1.2 Bolus or Fast-acting Insulins

          3. 5.2.2.1.3 Traditional Human Insulins

          4. 5.2.2.1.4 Combination Insulins

          5. 5.2.2.1.5 Biosimilar Insulins

        2. 5.2.2.2 Germany (Value and Volume, 2012-2025)

          1. 5.2.2.2.1 Basal or Long-acting Insulins

          2. 5.2.2.2.2 Bolus or Fast-acting Insulins

          3. 5.2.2.2.3 Traditional Human Insulins

          4. 5.2.2.2.4 Combination Insulins

          5. 5.2.2.2.5 Biosimilar Insulins

        3. 5.2.2.3 Italy (Value and Volume, 2012-2025)

          1. 5.2.2.3.1 Basal or Long-acting Insulins

          2. 5.2.2.3.2 Bolus or Fast-acting Insulins

          3. 5.2.2.3.3 Traditional Human Insulins

          4. 5.2.2.3.4 Combination Insulins

          5. 5.2.2.3.5 Biosimilar Insulins

        4. 5.2.2.4 Spain (Value and Volume, 2012-2025)

          1. 5.2.2.4.1 Basal or Long-acting Insulins

          2. 5.2.2.4.2 Bolus or Fast-acting Insulins

          3. 5.2.2.4.3 Traditional Human Insulins

          4. 5.2.2.4.4 Combination Insulins

          5. 5.2.2.4.5 Biosimilar Insulins

        5. 5.2.2.5 United Kingdom (Value and Volume, 2012-2025)

          1. 5.2.2.5.1 Basal or Long-acting Insulins

          2. 5.2.2.5.2 Bolus or Fast-acting Insulins

          3. 5.2.2.5.3 Traditional Human Insulins

          4. 5.2.2.5.4 Combination Insulins

          5. 5.2.2.5.5 Biosimilar Insulins

        6. 5.2.2.6 Russia (Value and Volume, 2012-2025)

          1. 5.2.2.6.1 Basal or Long-acting Insulins

          2. 5.2.2.6.2 Bolus or Fast-acting Insulins

          3. 5.2.2.6.3 Traditional Human Insulins

          4. 5.2.2.6.4 Combination Insulins

          5. 5.2.2.6.5 Biosimilar Insulins

        7. 5.2.2.7 Rest of Europe (Value and Volume, 2012-2025)

          1. 5.2.2.7.1 Basal or Long-acting Insulins

          2. 5.2.2.7.2 Bolus or Fast-acting Insulins

          3. 5.2.2.7.3 Traditional Human Insulins

          4. 5.2.2.7.4 Combination Insulins

          5. 5.2.2.7.5 Biosimilar Insulins

      3. 5.2.3 Latin America

        1. 5.2.3.1 Mexico (Value and Volume, 2012-2025)

          1. 5.2.3.1.1 Basal or Long-acting Insulins

          2. 5.2.3.1.2 Bolus or Fast-acting Insulins

          3. 5.2.3.1.3 Traditional Human Insulins

          4. 5.2.3.1.4 Combination Insulins

          5. 5.2.3.1.5 Biosimilar Insulins

        2. 5.2.3.2 Brazil (Value and Volume, 2012-2025)

          1. 5.2.3.2.1 Basal or Long-acting Insulins

          2. 5.2.3.2.2 Bolus or Fast-acting Insulins

          3. 5.2.3.2.3 Traditional Human Insulins

          4. 5.2.3.2.4 Combination Insulins

          5. 5.2.3.2.5 Biosimilar Insulins

        3. 5.2.3.3 Rest of Latin America (Value and Volume, 2012-2025)

          1. 5.2.3.3.1 Basal or Long-acting Insulins

          2. 5.2.3.3.2 Bolus or Fast-acting Insulins

          3. 5.2.3.3.3 Traditional Human Insulins

          4. 5.2.3.3.4 Combination Insulins

          5. 5.2.3.3.5 Biosimilar Insulins

      4. 5.2.4 Asia-Pacific

        1. 5.2.4.1 Japan (Value and Volume, 2012-2025)

          1. 5.2.4.1.1 Basal or Long-acting Insulins

          2. 5.2.4.1.2 Bolus or Fast-acting Insulins

          3. 5.2.4.1.3 Traditional Human Insulins

          4. 5.2.4.1.4 Combination Insulins

          5. 5.2.4.1.5 Biosimilar Insulins

        2. 5.2.4.2 South Korea (Value and Volume, 2012-2025)

          1. 5.2.4.2.1 Basal or Long-acting Insulins

          2. 5.2.4.2.2 Bolus or Fast-acting Insulins

          3. 5.2.4.2.3 Traditional Human Insulins

          4. 5.2.4.2.4 Combination Insulins

          5. 5.2.4.2.5 Biosimilar Insulins

        3. 5.2.4.3 China (Value and Volume, 2012-2025)

          1. 5.2.4.3.1 Basal or Long-acting Insulins

          2. 5.2.4.3.2 Bolus or Fast-acting Insulins

          3. 5.2.4.3.3 Traditional Human Insulins

          4. 5.2.4.3.4 Combination Insulins

          5. 5.2.4.3.5 Biosimilar Insulins

        4. 5.2.4.4 India (Value and Volume, 2012-2025)

          1. 5.2.4.4.1 Basal or Long-acting Insulins

          2. 5.2.4.4.2 Bolus or Fast-acting Insulins

          3. 5.2.4.4.3 Traditional Human Insulins

          4. 5.2.4.4.4 Combination Insulins

          5. 5.2.4.4.5 Biosimilar Insulins

        5. 5.2.4.5 Australia (Value and Volume, 2012-2025)

          1. 5.2.4.5.1 Basal or Long-acting Insulins

          2. 5.2.4.5.2 Bolus or Fast-acting Insulins

          3. 5.2.4.5.3 Traditional Human Insulins

          4. 5.2.4.5.4 Combination Insulins

          5. 5.2.4.5.5 Biosimilar Insulins

        6. 5.2.4.6 Vietnam (Value and Volume, 2012-2025)

          1. 5.2.4.6.1 Basal or Long-acting Insulins

          2. 5.2.4.6.2 Bolus or Fast-acting Insulins

          3. 5.2.4.6.3 Traditional Human Insulins

          4. 5.2.4.6.4 Combination Insulins

          5. 5.2.4.6.5 Biosimilar Insulins

        7. 5.2.4.7 Malaysia (Value and Volume, 2012-2025)

          1. 5.2.4.7.1 Basal or Long-acting Insulins

          2. 5.2.4.7.2 Bolus or Fast-acting Insulins

          3. 5.2.4.7.3 Traditional Human Insulins

          4. 5.2.4.7.4 Combination Insulins

          5. 5.2.4.7.5 Biosimilar Insulins

        8. 5.2.4.8 Indonesia (Value and Volume, 2012-2025)

          1. 5.2.4.8.1 Basal or Long-acting Insulins

          2. 5.2.4.8.2 Bolus or Fast-acting Insulins

          3. 5.2.4.8.3 Traditional Human Insulins

          4. 5.2.4.8.4 Combination Insulins

          5. 5.2.4.8.5 Biosimilar Insulins

        9. 5.2.4.9 Philippines (Value and Volume, 2012-2025)

          1. 5.2.4.9.1 Basal or Long-acting Insulins

          2. 5.2.4.9.2 Bolus or Fast-acting Insulins

          3. 5.2.4.9.3 Traditional Human Insulins

          4. 5.2.4.9.4 Combination Insulins

          5. 5.2.4.9.5 Biosimilar Insulins

        10. 5.2.4.10 Thailand (Value and Volume, 2012-2025)

          1. 5.2.4.10.1 Basal or Long-acting Insulins

          2. 5.2.4.10.2 Bolus or Fast-acting Insulins

          3. 5.2.4.10.3 Traditional Human Insulins

          4. 5.2.4.10.4 Combination Insulins

          5. 5.2.4.10.5 Biosimilar Insulins

        11. 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2025)

          1. 5.2.4.11.1 Basal or Long-acting Insulins

          2. 5.2.4.11.2 Bolus or Fast-acting Insulins

          3. 5.2.4.11.3 Traditional Human Insulins

          4. 5.2.4.11.4 Combination Insulins

          5. 5.2.4.11.5 Biosimilar Insulins

      5. 5.2.5 Middle-East and Africa

        1. 5.2.5.1 Saudi Arabia (Value and Volume, 2012-2025)

          1. 5.2.5.1.1 Basal or Long-acting Insulins

          2. 5.2.5.1.2 Bolus or Fast-acting Insulins

          3. 5.2.5.1.3 Traditional Human Insulins

          4. 5.2.5.1.4 Combination Insulins

          5. 5.2.5.1.5 Biosimilar Insulins

        2. 5.2.5.2 Iran (Value and Volume, 2012-2025)

          1. 5.2.5.2.1 Basal or Long-acting Insulins

          2. 5.2.5.2.2 Bolus or Fast-acting Insulins

          3. 5.2.5.2.3 Traditional Human Insulins

          4. 5.2.5.2.4 Combination Insulins

          5. 5.2.5.2.5 Biosimilar Insulins

        3. 5.2.5.3 Egypt (Value and Volume, 2012-2025)

          1. 5.2.5.3.1 Basal or Long-acting Insulins

          2. 5.2.5.3.2 Bolus or Fast-acting Insulins

          3. 5.2.5.3.3 Traditional Human Insulins

          4. 5.2.5.3.4 Combination Insulins

          5. 5.2.5.3.5 Biosimilar Insulins

        4. 5.2.5.4 Oman (Value and Volume, 2012-2025)

          1. 5.2.5.4.1 Basal or Long-acting Insulins

          2. 5.2.5.4.2 Bolus or Fast-acting Insulins

          3. 5.2.5.4.3 Traditional Human Insulins

          4. 5.2.5.4.4 Combination Insulins

          5. 5.2.5.4.5 Biosimilar Insulins

        5. 5.2.5.5 South Africa (Value and Volume, 2012-2025)

          1. 5.2.5.5.1 Basal or Long-acting Insulins

          2. 5.2.5.5.2 Bolus or Fast-acting Insulins

          3. 5.2.5.5.3 Traditional Human Insulins

          4. 5.2.5.5.4 Combination Insulins

          5. 5.2.5.5.5 Biosimilar Insulins

        6. 5.2.5.6 Rest of Middle-East and Africa (Value and Volume, 2012-2025)

          1. 5.2.5.6.1 Basal or Long-acting Insulins

          2. 5.2.5.6.2 Bolus or Fast-acting Insulins

          3. 5.2.5.6.3 Traditional Human Insulins

          4. 5.2.5.6.4 Combination Insulins

          5. 5.2.5.6.5 Biosimilar Insulins

  6. 6. MARKET INDICATORS

    1. 6.1 Type 1 Diabetes Population (2012-2025)

    2. 6.2 Type 2 Diabetes Population (2012-2025)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 COMPANY PROFILES

      1. 7.1.1 Novo Nordisk A/S

        1. 7.1.1.1 Overview

        2. 7.1.1.2 Products and Strategies

        3. 7.1.1.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.1.4 Ratio Analysis (5 Years)

        5. 7.1.1.5 Strength and Stability Analysis (5 Years)

        6. 7.1.1.6 Recent Developments

      2. 7.1.2 Sanofi S.A.

        1. 7.1.2.1 Overview

        2. 7.1.2.2 Products and Strategies

        3. 7.1.2.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.2.4 Ratio Analysis (5 Years)

        5. 7.1.2.5 Strength and Stability Analysis (5 Years)

        6. 7.1.2.6 Recent Developments

      3. 7.1.3 Eli Lilly and Company

        1. 7.1.3.1 Overview

        2. 7.1.3.2 Products and Strategies

        3. 7.1.3.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.3.4 Ratio Analysis (5 Years)

        5. 7.1.3.5 Strength and Stability Analysis (5 Years)

        6. 7.1.3.6 Recent Developments

      4. 7.1.4 Biocon Limited

        1. 7.1.4.1 Overview

        2. 7.1.4.2 Products and Strategies

        3. 7.1.4.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.4.4 Ratio Analysis (5 Years)

        5. 7.1.4.5 Strength and Stability Analysis (5 Years)

        6. 7.1.4.6 Recent Developments

      5. 7.1.5 Pfizer Inc.

        1. 7.1.5.1 Overview

        2. 7.1.5.2 Products and Strategies

        3. 7.1.5.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.5.4 Ratio Analysis (5 Years)

        5. 7.1.5.5 Strength and Stability Analysis (5 Years)

        6. 7.1.5.6 Recent Developments

      6. 7.1.6 Wockhardt

        1. 7.1.6.1 Overview

        2. 7.1.6.2 Products and Strategies

        3. 7.1.6.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

        4. 7.1.6.4 Ratio Analysis (5 Years)

        5. 7.1.6.5 Strength and Stability Analysis (5 Years)

        6. 7.1.6.6 Recent Developments

      7. 7.1.7 Julphar

        1. 7.1.7.1 Overview

        2. 7.1.7.2 Products and Strategies

        3. 7.1.7.3 Recent Developments

      8. 7.1.8 Exir

        1. 7.1.8.1 Overview

        2. 7.1.8.2 Products and Strategies

        3. 7.1.8.3 Recent Developments

      9. 7.1.9 Sedico

        1. 7.1.9.1 Overview

        2. 7.1.9.2 Products and Strategies

        3. 7.1.9.3 Recent Developments

    2. 7.2 COMPANY SHARE ANALYSIS

      1. 7.2.1 Novo Nordisk AS

      2. 7.2.2 Sanofi Aventis

      3. 7.2.3 Eli Lilly

      4. 7.2.4 Other Companies

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

Market size and volume of individual drugs provided for every country

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Human Insulin Drugs Market market is studied from 2016 - 2027.

The Human Insulin Drugs Market is growing at a CAGR of 4.19% over the next 5 years.

North America is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Biocon Limited, Pfizer Inc. are the major companies operating in Human Insulin Drugs Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!